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Genetic Predisposition to Testicular Germ-Cell Tumours
Introduction
The term testicular cancer encompasses a group of neoplasms that occur from childhood through 
to old age. This review focuses on germ-cell tumours of adolescents and adults, specifically 
seminomas and non-seminomas, which are thought to arise from carcinoma-in-situ.(28-30) We do 
not discuss paediatric germ-cell tumours or spermatocytic seminomas which do not  arise from 
carcinoma-in-situ and probably have a different cause from germ cell tumours in adolescents 
and adults.(28) We focus mainly on testicular germ-cell tumours (TGCT). However extragonadal 
germ-cell tumours of adolescents and adults have a very similar cause and arise from carcinoma-
in-situ; they can therefore be thought of as a part of the same disorder.
TGCT is the most common type of malignant disorder in men aged 15 - 40 years. The 
yearly incidence in this age group is about 7.5 per 100,000 people, but the incidence varies 
substantially between countries. (19;28;31) TGCT can be classified histologically as seminoma (about 
55%), which is most commonly diagnosed during the fourth decade of life, and non-seminoma 
(about 45%), which is generally diagnosed in the third decade of life. Both subtypes probably 
arise from preinvasive carcinoma-in-situ.(32;33)  The strongest risk factors for TGCT are a family 
history of the disorder(34;35), a previously diagnosed TGCT(36;37), and cryptorchism (undescended 
testis)(38-41,81). In addition, patients with Klinefelter’s syndrome(42) or XY gonadal dysgenesis(43) 
have a high risk of developing germ-cell tumours.(44) Other less strong risk factors documented 
and confirmed in several studies include: testicular atrophy(45), inguinal hernia(34), infertility(46;47), 
hydrocele(48), previously diagnosed extragonadal germ-cell tumour(44) and other disorders of male 
sexual differentiation. Many of the risk factors for TGCT include disorders of male urogenital 
differentiation. This feature has led to the term testicular dysgenesis syndrome (Figure 1), (12) and 
both environmental and genetic factors are probably involved.  In this review, we summarise the 
current knowledge of genetic predisposition to TGCT.
Clues to the existence of genetic predisposition 
Family history
1 –3% of patients with TGCT report an affected first-degree relative, a proportion higher than 
would be expected by chance (see Table 1).(35;48-57) The largest number of reported cases in 
a family is five,(58) but most familial clustering concists of relative pairs such as two affected 
brothers and to a smaller extent an affected father and son.(35;59) Figure 2 gives examples of 
familial clustering in TGCT. Brothers of patients with TGCT have a relative risk of TGCT of 8-10, 
and for father-son the relative risk is 4 – 6.(35;51;56) These relative risks for TGCT are higher than 
for most other cancer types, which rarely exceed 4. The high relative risk for TGCT is difficult to 
attribute only to a shared environmental component. To account for a relative risk greater than 
3 without some form of genetic predisposition requires that the environmental risk factor or 
factors are extremely potent. Khoury and colleagues(60) calculated that in this situation the risks 
Genetic Predisposition to Testicular Germ-Cell Tumours26 Genetic Predisposition to Testicular Cancer
2
27
to exposed people are 50-100 times those of unexposed individuals. Such potent risk factors 
have not yet been identified for TGCT.(61) 
Racial differences and geographic clustering
Geographic clustering of TGCT(62) and racial differences in the incidence of this disease could 
indicate a genetic component in the cause of the disease. The highest incidence is seen in white 
people of northern European descent, whereas people of African or Asian descent seem to 
have a universally low incidence.(28;59;61;63) The incidence of this disorder in African Americans is a 
quarter of that among white Americans(61) , and is similar to that of native African populations; 
thus the risk has not changed by much with migration to a new environment. Differences in 
incidence persisting after migration argue in favour of genetic rather than exogenous risk factors. 
This maintenance of risk contrasts sharply with the situation for cancers of breast, stomach, 
colon and ovaries, for which the incidence in immigrant populations tends rapidly towards that 
of the host population.(59;61;64;65) 
Table 1: First-degree familial TGCT and estimates of relative risk in male first-degree 
relatives of patients with TGCT 1985-2002
Author Year Study No. FTC / % FTC Sibs /  RR 
   total   Fath
   group*  -son     
Tollerud (48) 1985 Multicentre hospital-based,  6/269 2.2 2/4 5.9
  Retrospective 
Kruse (52) 1987 Single-centre hospital  3/255 1.2 3/0 NC
  based, Retrospective 
Patel (54) 1990 Multicentre hospital-based,  5/500 1.0 1/4 NC 
  Retrospective 
Forman (35) 1992 Multicentre hospital-based  12/794 1.5 8/4 9.8B
  and national population 
  based, Retrospective 
Westergaard (57) 1996 Data from Danish cancer  22/2261 1.0 10/12 12.3 
  registry, Retrospective    /1.96A
Polednak (55) 1996 Population-based  12/1395 0,86 8/4 NC
  Connecticut Tumor Registry 
Heimdal (51) 1996 Multicentre hospital-based,  32/1159 2.8 Nc 7.6
  Retrospective 
Dieckmann (49) 1997 Multicentre hospital-based,  18/1692 1.1/1.7 9/9 3.1
  Retrospective and  9/518  7/2 (retrospective  
  Prospective1    group)
Ondrus (53) 1997 Single-centre hospital  2/650  0.3 2/0 NC
  based, Retrospective 
Sonneveld (56) 1999 Single-centre hospital 
  based, Retrospective 17/686 2.5 11/6 8.5-12.7/1.7A
Dong et al.(50) 2001 Data from Swedish  62/4650 1.3% 38/24 8.3/3.9A
  family-cancer database,
  Retrospective 
FTC = familial testicular cancer 
NC = not calculated
* = Number of familial TGCT cases compared with total group.
RR = Relative Risk for all male first-degree relatives
A = RR for brothers / RR for fathers
B = RR only for brothers
1  = In a prospective multi centre study 18 of the 1692 patients had a first-degree relative with TGCT.
   Also a selection of patients from the Berlin (Germany) hospital were investigated: 518 patients, 
  9 had a first degree relative with TGCT.
Figure 1: The testicular dysgenesis syndrome. The asterisk indicates the possibility that cryptorchidism 
(testicular maldescent) acts as a causal risk factor. CIS: carcinoma in situ. Modified frame from: 
Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly 
common developmental disorder with environmental aspects. Hum Reprod. 2001;16:972–978.
© European Society of Human Reproduction and Embryology. 
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Bilateral TGCT and risk of other tumours
A consistent risk factor for the development of TGCT is having a previous testicular tumour. For 
patients who have had a first primary TGCT, the relative risk of developing a second is 25.(37;66) 
The prevalence of bilateral TGCT ranges between 1.0% and 5.8% and studies have even shown 
an increase.(67)  Bilateral involvement of paired organs (breast, retina, and kidney) has proved to 
be a clinical marker of hereditary cancer. Bilateral cases are commonly associated with a positive 
family history for the same tumours.(56) Heimdal and co-workers(51) found that 2.8% of patients 
with TGCT  who did not have a family history had bilateral disease compared with  9.8% of those 
with a positive family history. Bilateral disease in paired organs could also be the result of a very 
early somatic mutation (in embryogenesis), and evidence suggests that a proportion of bilateral 
TGCT could indeed be accounted for such a mechanism. Although mutations in the KIT (tyrosine 
kinase receptor) gene are rare in TGCT(68) and mediastinal germ-cell tumours(69) , mutations of 
this gene occur in a verry high proportion (95%) of tumours from patients with bilateral disease 
compared with a smaller proportion (3%) of tumours from those with unilateral disease.(70) When 
both tumours from bilateral cases could be assesed, the same mutation was present in both. 
Together these results suggest that somatic KIT mutations occur early in embryogenesis, before 
the primordial germ cells have divided and migrated to the gonads. Primordial germ cells with 
KIT mutations are therefore distributed to both testes; hence KIT mutations are associated with 
bilateral disease.(70)  In patients with a family history of TGCT, the frequency of KIT mutations 
in unilateral TGCT was similar to that detected previously by Looijenga and colleagues.(70) 
However, in patients with bilateral disease and a family history of TGCT, only 28% of tumours 
had mutations of KIT.(71) Although the reason for this difference is unclear, the evidence suggests 
that bilateral disease in the context of familial TGCT has a different pathogenesis from sporadic 
bilateral cases and that most familial bilateral cases are explained by the high risk conferred by 
the underlying inherited genes.(71)
A genetic predisposition to TGCT does not necessarily have to be site specific; in analogy with 
the situation with many proven hereditary tumour predispositions, patients with TGCT and 
their relatives could have an increased risk of developing non-TGCT tumours. Dong and co-
workers(50) investigated this trend in 4650 patients with TGCT and with a mean follow-up of 11 
years. They calculated a significantly increased standardised incidence ratio for various second 
primary tumours after testicular seminomas: TGCT 11.6 (95% CI 7.0-18.1), colorectal cancer 1.9 
(1.1-3.1), pancreatic cancer 3.8 (2.1-6.4), renal cancer 2.2 (1.1-4.0), bladder cancer 2.4 (1.5-3.7), 
thyroid cancer 5.4 (1.4-14.1) and malignant lymphomas 2.5 (1.3-4.1). Some of the second primary 
tumours could be associated with treatment, since seminomas (mostly treated by radiotherapy) 
were associated with a higher frequency of second malignant disorders than non-seminomas 
(mostly treated with chemotherapy). Furthermore, an analysis of the prevalence of tumours 
in relatives also showed an increased risk of TGCT in male relatives of patients with TGCT 
(standarised incidence ratio  8.3 for brothers and 3.8 for fathers and sons).(50) For all relatives 
together there was no excess risk of other cancer types in first-degree relatives of patients with 
Figure 2: 
Examples of familial clustering in TGCT. 
A. Brother pair, the most common type of pedigree. 
B. Father-son pair, the next most common relative pair. 
C. Cousin pair.
D. Uncle-nephew pair.  
E and F. Rare TGCT pedigrees with many affected cases.
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TGCT. However, mothers of patients with TGCT had significantly increased standarised incidence 
ratios for lung cancer (1.9; 95%CI 1.4-2.6), non-endometrial uterine cancer (2.6; 1.2-4.7), soft-
tissue tumours (2.5; 1.1-4.9) and malignant melanoma (1.8; 1.1-2.6). Other studies(72) have shown 
similar trends (although some not significant) of other cancers in mothers. However, all studies 
(57;73) show a high frequency of TGCT in relatives of patients with TGCT. These findings generally 
suggest that relatives of patients with TGCT have a greatly increased risk of developing TGCT 
but may not be at risk of developing other types of cancers.
Syndromic characteristics
Two constitutional chromosomal abnormalities are clearly associated with an increased risk 
of TGCT.  Patients with Klinefelter’s syndrome (47 XXY) have a very high risk of mediastinal, 
(extragonadal) germ-cell tumours.(74) About 8% of patients with such tumours have Klinefelter’s 
syndrome.(44) Patients with this syndrome rarely develop TGCT, probably because they do not 
have germ cells in the testis from shortly after birth; however, about a third of patients with 
extragonadal germ-cell tumours present with testicular carcinoma-in-situ and these patients have 
a substantial risk of developing TGCT (see later).(44;75;76) Patients with XY gonadal dysgenesis 
have a greatly increase risk of germ-cell tumours.(74;77) This increased risk is seen only in patients 
with Y chromosome material; those with gonadal dysgenesis and  XX or 45X karyotype do not 
have an increased risk of TGCT.(51;76;77) Patients with Down’s syndrome (trisomy 21) might also be 
at increased risk of TGCT but the numbers are too small for firm conclusions to be drawn. (78;79)
The presence of TGCT in a hereditary syndrome might be an indication of a hereditary 
predisposition to TGCT. We have described the prevalence of TGCT in patients with various 
hereditary disorders.(76) Owing to the rarity of most of these disorders and the scarce reports 
of their occurrence in combination with TGCT, at present there is no statistical proof of an 
association of TGCT with these disorders. An important clinnical issue is that in a proportion 
of these disorders there is also a range of defects in urogenital differentiation, which suggests 
that TGCT in these disorders is indeed a further complication of such a differentiation defect, as 
postulated in the model of Skakkebaek and colleagues (figure 1).(12)
Cryptorchism and other disorders of testicular differentiation in patients and relatives
Cryptorchism and other testicular abnormalities such as atrophy, infertility, hydrocele and 
inguinal hernia are risk factors for TGCT.(34;45;46;80;81) As regards family history, Forman and co-
workers(35) showed that the frequency of cryptorchism in patients with TGCT did not differ 
between those with or without a positive family history. However, very few studies have looked 
at the frequencies of these risk factors in male relatives of patients with TGCT. A small study 
by Tollerud and colleagues(48) showed that cryptorchism occurred in a significantly greater 
proportions of first-degree male relatives of patients with a family history of TGCT (17%) than 
of relatives of patients with TGCT who did not have such a family history (5.3%) or of controls 
(2.7%). Their study also showed that 50% of patients who had TGCT and a family history 
reported a first-degree relative with inguinal hernia, compared with 10.3% of those without a 
family history and with 12.7% of controls. The high prevalence of cryptorchism, inguinal hernias, 
and hydrocele among men in these families suggests that an underlying alteration in urogenital 
embryogenesis could be associated with the familial predisposition to testicular neoplasia.  
Studies on Twins
Studies on twins with cancer have been used to address two general issues.  First, are there any 
carcinogenic effects of twinning? This question can be answered by comparison of the occurrence 
of a cancer in twins and in singletons. The second issue, what the heritable components are to 
that cancer, can be addressed by a proband-wise analysis ( proband = the affected individual 
through whom a family with a genetic disorder is ascertained) of monozygotic twins compared 
with dizygotic twins or siblings. If there is a heritable component the relative risk should be 
higher for monozygotic than for dizygotic twins.
In a cohort of 14326 elderly twins aged 66 – 77 years, Braun and co-workers(82) noted that a 
personal history of TGCT was reported by five (0.08%) of 5951 monozygotic twins and 11 (0.16%) 
of 6992 dizygotic twins. Swerdlow and colleagues(83) als found a significantly higher risk of 
TGCT in dizygotic than in monozygotic twins (odds ratio 1.5; 95% CI 1.1-2.2).(83) These finding 
suggest that an environmental component was acting in utero to cause TGCT. To find a possible 
genetic effect, twin studies must asses the risk of TGCT in the twin brothers of affected patients; 
however, the numbers are too small in many studies for any conclusions to be drawn. Swerdlow 
and colleagues(83) identified six pairs of concordant (both affected) twins. The risk of TGCT was 
raised in twin brothers of patients with TGCT (relative risk 37.5; 95% CI 12.3 – 115.6) and was 
greater in monozygotic (76.5) than dizygotic (35.7) twins, which would be expected if there 
is a heritable part to TGCT. This relative risk is several times that found in non-twin brothers 
(although the confidence limits are wide because of small numbers) but it does imply that the 
genetic element for risk is far larger for TGCT than for most other cancers. Other twin studies 
on TGCT have not had sufficient numbers of concordant twin pairs and have been unable to 
determine zygosity so could not confirm this result.
Environmental components 
The worldwide incidence of TGCT has more than doubled over the past 40 years. The increase 
follows a birth-cohort effect, and a probable explanation is that factors in embryogenesis or 
early life are contributing to the development of TGCT.(28;84;85)  The rapid increase highlights 
the importance of environmental factors in this disease, because the genetic composition of a 
population simply cannot change in the course of one or two generations. Why this increase is 
occuring is unclear, but one theory is that an increase in endogenous oestrogens is contributing 
to increase in TGCT in addition to risk factors for the disorder such as the increase in incidence 
of cryptorchism and the decrease in fertility and sperm quality.(86;87) Another hypothesis is that 
abnormally high oestrogen concentrations in pregnancy predispose the developing gonad to 
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TGCT in adulthood. Direct investigation of this idea is difficult, and many studies have looked at 
surrogate features that could reflect high oestrogen concentrations in pregnancy.(87)  According to 
this hypothesis, a high rate of TGCT in dizygotic twins (because uterine oestrogen concentration 
during pregnancy are higher for dizygotic than for monozygotic twins), as well as older ages of 
mothers and a higher rate of oestrogen related cancers (eg, breast cancer) in mothers and sisters 
would be expected.(88) Overall published reports(87;88)  provide conflicting results on the analysis 
of these variables. These features are merely weak indicators of high oestrogens concentrations, 
so the sample size and statistical power of many of these case-control studies might have 
been too low to show any significant association. Although hormonal factors could be causally 
involved in the development of TGCT, mothers of patients with TGCT do not have an increased 
risk of oestrogen related cancer and the risks of breast cancers does not seem to be increased 
in the sisters of these patients.(50;72) Even though many studies have showed similar results, this 
hypothesis remains unconfirmed.    
Several studies have confirmed a higher frequency of TGCT in dizygotic twins than in singletons 
and monozygotic twins. This difference suggests that the concentration of circulating oestrogen, 
which is significantly higher in pregnancies with dizygotic than in those with monozygotic twins 
or singletons, is a contributory causative factor.(82;83;88) However, more research is needed into 
the pathogenetic mechanisms that could cause the increase risk of TGCT in dizygotic twins. 
Twinning itself is to a sustantial extent genetically determined, and coinherited genetic factors 
could conceivably be contributing to this increase rather than circulating oestrogens.
 
Modelling studies 
Two studies so far have tried to identify the mode of inheritance of TGCT susceptibility genes. 
One was based on the frequency of bilateral TGCT,(89) and the other was a segregation analysis 
on a group of Norwegian and Swedish families.(90) In a segregation analysis, a disease model 
is sought for familial aggregation of a disease by fitting the patients and non-affected family 
members in pedigrees to, for example, a dominant or recessive disease model. Heimdal and 
colleagues(90) did such an analysis on all available patients with TGCT treated at a Norwegian 
hospital and a Swedish hospital between 1981 and 1991 (n=978). For 30 patients, a first-degree 
relative also had TGCT; there were no families with more than two affected members. The 
investigators concluded that the familial clustering was best accounted for by a major gene for 
TGCT with a recessive mode of inheritance. Their analysis took into account that the incidence 
of TGCT has increased substantially over the past few years and that the treatment for TGCT 
has improved greatly and led to better maintenance of fertility and longer survival. The study 
showed that time trends in TGCT make little difference to the evidence for the recessive mode of 
inheritance.(90)  Under this recessive model, the estimated gene frequency was 3.8%. Thus 7.3% 
(according to the Hardy-Weinberg equilibrium) of men in the population carry the mutant allele 
and that 0.1% are homozygous. According to the calculations by Heimdal and colleagues, the 
life-time risk of development of TGCT in homozygous men is 43%.(90) 
Nicholson and Harland(89) aimed to define the incidence of genetically determined TGCT in 
the general population. They analysed published data on the age of onset of TGCT and the 
prevalence of bilateral TGCT in familial and unselected general cases according to the arguments 
used by Knudson’s two-hit model for tumorigenesis in patients with a familial predisposition 
to a certain cancer.(91) In the general population bilateral TGCT occurs much more frequently 
than could be attributed to chance. On the basis of the comparison of the distribution of age 
at diagnosis between patients with bilateral TGCT and familial cases (ie, those likely to be 
genetically determined), the investigators assumed in their model that the increased risk was 
due solely to genetic susceptibility. Thus patients with bilateral TGCT probably carry the same 
susceptibility genotype as that causing familial TGCT. Nicholson and Harland(89) estimated that 
about a third of the general patients with TGCT carry the susceptibility genotype and that the 
penetrance is 0.45. Calculations with these values showed that a recessive disease model 
showed a better fit with the observed risks for brothers (2.2%) and fathers (0.5%) of patients 
with TGCT than a dominant disease model. The frequency of the susceptibility allele in the 
recessive model was estimated to be 5%. Although this analysis, based on the simplest set of 
assumptions, fitted the data reasonably well, Nicholson and Harland conceded that it was based 
on data obtained under diverse conditions and could be subject to several unknown biases. 
Therefore, the assumptions that underlie the model might be incorrect.  They also conceded 
that some unilateral tumours may be predisposed to a contralateral tumour by some as yet 
unknown biological mechanism (indeed, such a mechanism was later identified as early somatic 
KIT mutations, as iscussed above) or that there is more than one predisposition gene and that 
the mode of inheritance is more complex.
X-linkage was not specifically addressed by the two studies mentioned. The higher relative risk 
for  brothers than for father-son pairs is compatible with a recessive mode of inheritance, but 
since the early 1990s the incidence of TGCT has increased sharply, maintenance of fertility after 
treatment for TGCT has improved greatly, and the introduction of cisplatin-based chemotherapy 
has substantially lowered the number of deaths from TGCT.(92-94) These changes might lead to a 
situation in which the relative risk for father-son is higher than was believed initially.  A further 
possibility is that because of shorter survival (ie, a lower chance that a TGCT patient will father 
a child) and abolition of fertility in the past (before the 1990s), less transmission of TGCT from 
father to son was seen. Although the study by Heimdal and colleagues(90)   tried to take this 
factor into account, the investigators admitted that to do so is very difficult and that more 
complex assumptions are involved. The study by Nicholson and Harland(89)  made allowance 
for the time trends, but partly because only two studies have attempted to define the mode of 
inheritance, there is a risk that the conclusion of inheritance according to a recessive model is 
incorrect. A dominant form of inheritance should therefore not be totally excluded. Because a 
proportion of bilateral cases are caused by early somatic mutations in KIT and because there is 
clearly more than one TGCT susceptibility gene, susceptibility to TGCT is probably more complex 
than suggested by either of these models.
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Association studies and haplotype analyses
Association studies try to find statistical evidence of an association between polymorphic loci 
on, or closely linked to, candidate genes (eg, genes involved in the metabolism of mutagenic 
agents, known tumour-suppressor genes or oncogenes) and a particular phenotype (eg, TGCT) 
by comparing frequencies between cases and controls. Because TGCT is a rare disease and 
mapping of the causal genes is difficult,  TGCT patients and  families from founder populations 
are very suitable people in whom to detect TGCT predisposition genes with the aid of 
association or haplotype analyses.(95;96)  Patients in founder populations are expected to share a 
high number of mutations predisposing to TGCT from recent common ancestors.(62) They will also 
share segments of DNA surrounding the disease mutations. Haplotypes consisting of conserved, 
ancestral alleles at genetic markers covering the region of a disease mutation will therefore be 
more frequent among patients than among controls.
Several association studies have been done on TGCT. In Table 2, an overview is given of these 
studies. Much attention has been paid to HLA genes and TGCT. The HLA region is thought to be 
interesting for such studies, because differences in immune response based on HLA variation 
might have a role in the development of cancer and metastases. Hodgkin’s lymphoma, Kaposi’s 
sarcoma, colorectal cancer and breast cancer are associated with this genomic region.(97;98) The 
effects (based on HLA variation) of the immune response to carcinogenic factors such as viruses 
that might be associated with TGCT, could contribute to the development of the disorder.(99;100) 
Previous studies have shown that HLA factors might be associated with the development of 
TGCT. In particular, consistent associations were found with the HLA class II antigens. No 
association was found with the HLA A or C regions, and inconsistent associations were found 
with the HLA B region(96) (Table 2). The method used in most studies was serotyping, which is 
much less accurate and less efficient than the more recent genotyping studies. DNA typing is 
far more sensitive and can identify larger numbers of alleles.(101) The first HLA genotyping study 
by Özdemir and colleagues(102)   in 55 Japanese patients, showed  two associations: one HLA 
susceptibility allele and one HLA protective allele (relative risk 3.26 and 0.26 respectively). A 
much larger genotyping study on the HLA class II region of chromosome 6p21 in 151 patients 
from the northern part of the Netherlands could not replicate this association.(96) The association 
between TGCT and HLA class II alleles either does not exist or is much weaker than the earlier 
report suggested.  
The other association studies in Table 2 give an overview of the diverse associations that 
researchers have attempted to show with TGCT. In many cases, only one study has investigated 
a certain region. To date, no convincing associations has been shown between TGCT and a 
genetic polymorphism. 
Linkage analysis and genome-wide screens
Linkage analysis relies on the fact that during the formation of gametes through meiosis 
chromosomal material is exchanged between homologous chromosomes. This recombination 
of genes means that were once on the same homologue of a particular chromosome pair 
become separated and those once on different homologues are brought together. The process 
of recombination is achieved by crossing-over of the chromosomes during meiosis. The 
probability that a cross-over will occur and two loci on the same chromosome will randomly 
segregate increases with the distance between the genetic loci. For two genes close together 
on a chromosome, a cross-over is unlikely to occur and the two loci will be inherited together. 
Linkage analysis uses this feature to map genes by means of a series of polymorphic genetic 
markers (microsatelite markers or single-nucleotide polymorphisms) along the chromosomes 
to follow the inheritance pattern of marker loci and the disease locus through a family. If a 
particular polymorphism or marker is inherited by a higher proportion of patients than would 
be expected by chance, the locus is said to be linked to the disease and is in fact probably 
very closely located to the disease locus on the DNA strand. Since the position of the marker 
locus is known, the location of the unknown disease locus is then found. Linkage analysis in a 
set of pedigrees with many cases of a cancer has identied genes associated with breast cancer, 
colon cancer, familial melanoma, and others. For many of these cancers the pedigrees used had 
many affected cases spread over several generations. In many cases, a single pedigree provides 
sufficient numbers of affected cases to generate a statistically significant LOD score (logarithm 
of odds, a statistic that indicates whether a locus is inherited by a higher proportion of patients 
than expected by chance). The search for a TGCT susceptibility gene has been hampered by 
a lack of these large multigenerational pedigrees. Most families identified are relative pairs, 
generally siblings. Larger pedigrees with three, four or five affected cases have been reported 
but these rarely extend beyond two generations.  
The International Testicular Cancer Linkage Consortium (ITCLC) has the largest collection of 
TGCT pedigrees with two or more cases of TGCT in a family.(103)  An analysis by this group has 
shown that no single autosomal gene accounts for all TGCT pedigrees.(104)  The analysis of 160 
TGCT pedigrees consisted of calculations under the best autosomal dominant and autosomal 
recessive models given by the segregation analysis of Heimdal and colleaguesl(90), but allowing 
for the possibility of genetic heterogeneity (ie, several genes are involved separately or in 
interaction with each other). An X-linked component to susceptibility was not considered. The 
analysis suggests that this set of pedigrees has sufficient power to detect two TGCT genes each 
contributing to 50% of the set with a statistically significant LOD score greater than 3 under 
both a dominant and a recessive model. The analysis also investigated the power to detect four 
TGCT susceptibility genes each contributing to a quarter of the family set. In this case, significant 
LOD scores would not be possible unless the number of families in the set approached 500 
pedigrees. The last report by the ITCLC was on a total of 179 pedigrees and the failure to find 
LOD scores greater than 3 in any autosomal locus suggests that no single locus can explain 
occurrence of TGCT in at least 50% of the families. It  also suggests that there are more than 
two TGCT susceptibility genes.(103) The power to detect some or all of the susceptibility genes 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































for TGCT will depend greatly on the degree of genetic heterogeneity of this disease.  Continued 
identification and recruitment of families into this linkage study will be crucial to the efforts to 
identify these genes.
The first evidence for a TGCT susceptibility gene was for the X chromosome.(105) The analysis on 
99 pedigrees compatible with X linkage (no male-to-male transmission) yielded a heterogeneity 
LOD score of 2.01 on chromosome Xq27.  The data were subsequently stratified according to 
the presence of at least one bilateral case, the presence of undescended testis, histology, and 
age. Families with at least one case of bilateral disease showed strong evidence of linkage to 
a locus on Xq27 (heterogeneity LOD score 4.76) and were more likely to show linkage to the X 
chromosome than were families without a bilateral case. This score corresponds to a genome-
wide significance of p=0.034, equivalent to a LOD score of 3.78 in a genome-wide linkage search 
of affected sibling pairs without subgrouping. This proposed susceptibility gene on chromosome 
Xq27 was called TGCT1.(105) In Klinefelter’s syndrome, the increased risk of extragonadal germ-cell 
tumours is associated with an extra copy of the X chromosome which further suggests X-linked 
involvement in TGCT.(75;105) In addition, the subset analysis provided evidence that the TGCT1 
might also predispose to cryptorchism. Linkage to this locus was found in 73% of families with 
cryptorchism compared with 26% of families without cryptorchism (p=0.03). The results also 
suggest that about a third of the excess familial TGCT risk to brothers is from TGCT1, with little 
difference in the residual risks to brothers and sons after this locus has been accounted for. This 
is the first cancer gene to be mapped in a genome wide search of predominantly sibling pairs 
and was the third male cancer gene mapped to the X chromosome.(105)
Conventionally, such a result would be ratified in another set of families; however no other set 
of TGCT pedigrees of similar size is known. These pedigrees are rare and collection of a similar-
sized set may take several years. The ITCLC reported preliminary results on an additional 25 
pedigrees compatible with X linkage but the set was to small for any firm conclusions to be 
drawn.(103) The gene in this region has not been identified.
TGCT1 is unlikely to be the only TGCT susceptibility gene and it could account for as few as 
25% of all TGCT pedigrees. Several genome searches have now been done on the ITCLC set, 
and suggestive evidence for linkage has been obtained for several autosomal regions including 
3q27, 12q12-q13, 16p13, 18q22 – qter.(103) Many more pedigrees need to be assesed before any 
of these regions can be conclusively identified as including a TGCT susceptibility gene.
Discussion
There is evidence that TGCT susceptibility genes exist and are important in this disease.
This evidence includes increased TGCT risks associated with a positive family history, the higher 
frequency of bilaterality in familial cases and the ethnic and racial differences that do not 
change with migration, as well as the mathematical modelling of observed familial and non-
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familial cases, and possible associations with known hereditary syndromes and constitutional 
chromosomal anomalies; the latter commonly seen within the setting of defects in urogenital 
differentiation.
Human TGCT susceptibility genes have not yet been identified. The putative gene mapped to 
Xq27 is postulated to confer an increased risk of TGCT as well as cryptorchism. Completion of 
the human gene map, further studies on animal models, the arrival of advanced gene arrays 
(chips), genome-wide single- nucleotide polymorphism technology, and applied bioinformatics 
are expected to facilitate further exploration of genetic predisposition to TGCT. One point of 
interest is whether such predisposition can be linked to a genetic contribution from increased 
intrauterine oestrogen concentrations and susceptibility to disruption of usual urogenital 
differentiation or to an environmental factor that would account for the increasing incidence 
of TGCT. Insight into genetic features of TGCT not only might contribute to the identification 
of individuals at increased risk of developing the disorder, but also is likely to increase our 
understanding of normal urogenital differentiation and non-hereditary TGCT. This knowledge will 
contribute to improving the diagnosis and treatment of TGCT in the general population. From 
a practical clinical perspective, identification of men with an increased risk of TGCT depends 
on the presence of known risk factors, including the family history of cancer. Clinicians should 
therefore record the family history of cancer and urogenital differentiation defects as part of their 
routine clinical practice in patients with TGCT or urogenital differentiation defects. Brothers of 
patients with TGCT should be informed about their risk of developing the disorder and should 
be encouraged to examine their testicles regularly. The US National Cancer Institute and the 
ITCLC are doing a genetic and causal multidisciplinary study of familial TGCT. (http://familial-
testicular-cancer.cancer.gov/). However, unlike some other increased risk situations determined 
by positive family histories (eg, those of colorectal cancer), the effects of preventive measures, 
including testis self-examination, in terms of tumour risk as well as psychosocial effects remain 
to be investigated. 
Search strategy and selection criteria
Articles and studies included in this review were identified by searches of titles, abstracts and 
keywords of reports included in PubMed and through the list of references cited by the papers 
found by those PubMed searches. Searches were done with combinations of the search terms:
” testicular”, “seminoma”, “non-seminoma”, ”familial”, “risk factors”, “genetic”, “tumo(u)r”, 
“gene(s)”, “linkage” and “association”. Papers published before 1970 and those published in 
languages other than English, French and German were excluded.
 
 
